Literature DB >> 15652609

Treating individuals 3: from subgroups to individuals: general principles and the example of carotid endarterectomy.

Peter M Rothwell1, Ziyah Mehta, Sally C Howard, Sergei A Gutnikov, Charles P Warlow.   

Abstract

Clinicians often have to make treatment decisions based on the likelihood that an individual patient will benefit. In this article we consider the relevance of relative and absolute risk reductions, and draw attention to the importance of expressing the results of trials and subgroup analyses in terms of absolute risk. We describe the limitations of univariate subgroup analysis in situations in which there are several determinants of treatment effect, and review the potential for targeting treatments with risk models, especially when benefit is probably going to be dependent on the absolute risk of adverse outcomes with or without treatment. The ability to systematically take into account the characteristics of an individual patient and their interactions, to consider the risks and benefits of interventions separately if needed, and to provide patients with personalised estimates of their likelihood of benefit is shown using the example of endarterectomy for symptomatic carotid stenosis.

Entities:  

Mesh:

Year:  2005        PMID: 15652609     DOI: 10.1016/S0140-6736(05)17746-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  62 in total

1.  A new taxonomy for stakeholder engagement in patient-centered outcomes research.

Authors:  Thomas W Concannon; Paul Meissner; Jo Anne Grunbaum; Newell McElwee; Jeanne-Marie Guise; John Santa; Patrick H Conway; Denise Daudelin; Elaine H Morrato; Laurel K Leslie
Journal:  J Gen Intern Med       Date:  2012-04-13       Impact factor: 5.128

2.  N-of-1 trials: an opportunity to tailor treatment in individual patients.

Authors:  Vishnu Madhok; Tom Fahey
Journal:  Br J Gen Pract       Date:  2005-03       Impact factor: 5.386

Review 3.  Symptomatic and asymptomatic carotid stenosis: how, when, and who to treat?

Authors:  Peter M Rothwell
Journal:  Curr Atheroscler Rep       Date:  2006-07       Impact factor: 5.113

4.  Atherothrombosis and ischaemic stroke.

Authors:  P M Rothwell
Journal:  BMJ       Date:  2007-02-24

Review 5.  Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects.

Authors:  David M Kent; Ewout Steyerberg; David van Klaveren
Journal:  BMJ       Date:  2018-12-10

6.  Diagnostic accuracy of colour Doppler ultrasonography, CT angiography and blood-pool-enhanced MR angiography in assessing carotid stenosis: a comparative study with DSA in 170 patients.

Authors:  M Anzidei; A Napoli; F Zaccagna; P Di Paolo; L Saba; B Cavallo Marincola; C Zini; G Cartocci; L Di Mare; C Catalano; R Passariello
Journal:  Radiol Med       Date:  2011-03-07       Impact factor: 3.469

7.  Evaluating marker-guided treatment selection strategies.

Authors:  Roland A Matsouaka; Junlong Li; Tianxi Cai
Journal:  Biometrics       Date:  2014-04-29       Impact factor: 2.571

8.  Secular Trends in Procedural Stroke or Death Risks of Stenting Versus Endarterectomy for Symptomatic Carotid Stenosis.

Authors:  Mandy D Müller; Stefanie von Felten; Ale Algra; Jean-Pierre Becquemin; Richard Bulbulia; David Calvet; Hans-Henning Eckstein; Gustav Fraedrich; Alison Halliday; Jeroen Hendrikse; George Howard; John Gregson; Olav Jansen; Martin M Brown; Jean-Louis Mas; Thomas G Brott; Peter A Ringleb; Leo H Bonati
Journal:  Circ Cardiovasc Interv       Date:  2019-08-05       Impact factor: 6.546

9.  Patent foramen ovale in cryptogenic stroke: incidental or pathogenic?

Authors:  Alawi A Alsheikh-Ali; David E Thaler; David M Kent
Journal:  Stroke       Date:  2009-05-14       Impact factor: 7.914

Review 10.  Rethinking trial strategies for stroke and patent foramen ovale.

Authors:  David E Thaler; David M Kent
Journal:  Curr Opin Neurol       Date:  2010-02       Impact factor: 5.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.